期刊文献+

阴茎勃起功能障碍合并良性前列腺增生症相关下尿路症状的治疗

Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis
下载PDF
导出
摘要 50岁以上的男性有4种非肿瘤性疾病最常见,包括阴茎勃起功能障碍(erectile dysfunction,ED)、良性前列腺增生(benign prostate hyperplasia,BPH)、心血管疾病和抑郁症,且发病率随着年龄的增长而增高。BPH是导致下尿路症状(lower uri-nary tract symptoms,LUTS)的主要病因, Lower urinary tract symptoms secondary to benign prostatic hyperplasia(BPH/LUTS) anderectile dysfunction(ED) are common conditions seen in aging males.Although the exact mechanism ofED combined BPH/LUTS is unknown,treatment with α-adrenergic receptor resistance agents(α-ARAs) that the associations between BPH/LUTS and ED lay the foundation for future therapies and possible pre-ventative strategies.This article has mainly summarized the advancement of epidemiology,basic research and treatment of ED combined with BPH/LUTS with α-receptor blockers and phosphodiesterase-5 inhibitors.
作者 金哲 辛钟成
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2011年第4期632-635,共4页 Journal of Peking University:Health Sciences
基金 国家自然科学基金(30972993)资助~~
关键词 勃起功能障碍 前列腺增生 肾上腺素能Α拮抗剂 磷酸二酯酶抑制剂 Erectile dysfunction Prostatic hyperplasia Adrenergic alpha-antagonists Phosphodieste-rase inhibitors
  • 相关文献

参考文献2

二级参考文献25

  • 1Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
  • 2Asian G, Cavus E, Karas H, Oner O, Duran F, et al. Association between lower urinary tract symptoms and erectile dysfunction. ArchAndrol 2006; 52: 155~2.
  • 3Girman C J, Jacobsen S J, Tsukamoto T, Richard F, Garraway WM, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36.
  • 4Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Uro12004; 46: 547-54.
  • 5Chapple CR. Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-44.
  • 6Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension. A double-blind, placebocontrolled, doseresponse multicenter study. J Urol 1995; 54: 110-5.
  • 7Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
  • 8Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1- adrenoceptor antagonists. BJU Int 2005; 95: 29-36.
  • 9Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163: 1725-9.
  • 10Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-62.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部